A Phase 4 interventional study of Rosuvastatin and Rosuvastatin/ezetimibe in Coronary Artery Disease, Atherosclerosis of Coronary Artery and Plaque, Atherosclerotic, sponsored by Korea University Anam Hospital. Active, not recruiting at 7 sites in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Korea University Anam Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing rosuvastatin in Coronary Artery Disease — 2 open to participants now, 5 under way, 1 of them phase 3. rosuvastatin · Coronary Artery Disease.
Among the 34 studies testing rosuvastatin in Coronary Artery Disease, this one is the 7th largest by enrollment, is one of 2 that started in 2025, is one of 22 in phase 4, and was the 33rd registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →2 of the 34 studies testing rosuvastatin in Coronary Artery Disease are open now, in 2 countries. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 30–60
Prof. Maurovich-Horvat Pál · Sites in Hungary
Ages 45–75
By country, each count listing its studies:
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 410 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 175 across the 34 interventional studies. Of the 14 that completed or were terminated, 3 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 34 have an industry lead sponsor. The 10 most frequent:
Korea University Anam Hospital is the lead sponsor of 114 studies on the registry; 33 are open to participants now.
Korea University Anam Hospital has 8 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
3 of the studies testing rosuvastatin in Coronary Artery Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03169985Samsung Medical CenterRandomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque | 2027-01-28 |
| NCT05850091Massachusetts General HospitalPolygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine | 2027-06-01 |
| NCT06767345Korea University Anam HospitalComparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 34 studies testing rosuvastatin in Coronary Artery Disease, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a prospective, multicenter, randomized clinical trial aimed at comparing the effects of moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy on coronary plaque stabilization. Using advanced imaging techniques such as near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS), the trial evaluates whether the combination therapy is non-inferior to monotherapy in stabilizing coronary plaques over 52 weeks. The primary endpoint is the change in percent atheroma volume (PAV) from baseline to week 52, assessed by grayscale IVUS. Secondary outcomes include changes in lipid core burden, inflammatory markers, and clinical events like myocardial infarction and ischemic stroke. Seven hospitals participated in the study. A total of 410 participants were enrolled at six sites; no participants were enrolled at Inje University Ilsan Paik Hospital. Follow-up is ongoing.
The criteria were revised on the registry on Oct 6, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least one major native coronary artery ("target vessel") meeting all the following criteria for intracoronary imaging immediately following a qualifying PCI procedure:
Exclusion Criteria:
Women of (under 50 years of age) who:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rosuvastatin 20 mg once daily
Drug: Rosuvastatin
Rosuvastatin 10mg plus Ezetimibe 10mg fixed dose single-pill combination
Drug: Rosuvastatin/ezetimibe
Rosuvastatin 20mg once daily
Drug pages: RosuvastatinStudies of RosuvastatinRosuvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EzetimibeStudies of EzetimibeEzetimibe pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Rosuvastatin 10mg + Ezetimibe 10mg
Change in percent atheroma volume (PAV) from baseline to week 52, assessed by gray-scale IVUS
Percent atheroma volume (PAV) is calculated within matched coronary-artery regions of interest as 100 × Σ(EEM CSA - lumen CSA)/Σ(EEM CSA), where EEM CSA is the external elastic membrane cross-sectional area and lumen CSA is the lumen cross-sectional area. Change in PAV between baseline and week 52 is assessed by gray-scale IVUS.
Time frame: 52 weeks
Change from baseline to week 52 in total lipid core burden index measured by NIRS (LCBItotal)
Time frame: 52 weeks
Changes in NT-pro-BNP from baseline to 52 weeks and associations with plaque progression/regression indices
Time frame: 52 weeks
Changes in hsTnT from baseline to 52 weeks and associations with plaque progression/regression indices
Time frame: 52 weeks
Changes in hsCRP from baseline to 52 weeks and associations with plaque progression/regression indices
Time frame: 52 weeks
Cataract incidence from baseline to 52 weeks
Time frame: 52 weeks
Adherence from baseline to week 52 (80% or greater)
Proportion of patients achieving ≥80% adherence to prescribed medication from baseline to week 52
Time frame: 52 weeks
Incidence of statin-associated muscle syndrome (SAMS) from baseline to week 52
Time frame: 52 weeks
Incidence of new diabetes from baseline to week 52
Time frame: 52 weeks
Ischemic Stroke/TIA from Baseline to Week 52
Time frame: 52 weeks
Ischemic Coronary Revascularization From Baseline to Week 52
Time frame: 52 weeks
Nonfatal myocardial infarction from baseline to week 52
Time frame: 52 weeks
Cardiac-related deaths from baseline to week 52
Time frame: 52 weeks
All deaths from baseline to week 52
Time frame: 52 weeks
Changes in LDL-cholesterol from baseline to 52 weeks and associations with plaque progression/regression indices
LDL-cholesterol levels measured in mg/dL. Blood samples will be collected at baseline and after 52 weeks.
Time frame: 52 weeks
Change in maximum LCBI within a 4-mm bin measured by NIRS from baseline to week 52 (maxLCBI4mm)
Time frame: 52 weeks
Change in corrected total atherosclerotic plaque volume (NTAV) measured by IVUS from baseline to week 52
Time frame: 52 weeks
Plan to share: Undecided
Started May 2025 (actual). Primary completion is estimated for Nov 2027, 30 months after the start.
Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 30 months is below that.
Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.
Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2028 → Nov 2027, on Oct 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rosuvastatin · Ezetimibe
Korea University Anam Hospital →